Gossamer Bio Receives 'Hold' Rating from Analysts

Biotech firm's stock faces mixed reviews from research firms

Mar. 29, 2026 at 8:42am

Got story updates? Submit your updates here. ›

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have received a consensus 'Hold' rating from the 10 research firms currently covering the company, according to a report from MarketBeat. The average 12-month price target among analysts is $5.43.

Why it matters

Gossamer Bio is a clinical-stage biotech company focused on developing therapies for immune-mediated and inflammatory diseases, as well as oncology. The 'Hold' rating and mixed analyst views could impact investor sentiment and the company's ability to raise capital for further drug development.

The details

The analyst ratings for Gossamer Bio include two 'Sell' recommendations, four 'Hold' ratings, and four 'Buy' recommendations. Some firms have lowered their price targets on the stock, with HC Wainwright decreasing its target from $10 to $5.

  • Gossamer Bio released its latest quarterly earnings report on March 17, 2026.

The players

Gossamer Bio, Inc.

A clinical-stage biopharmaceutical company headquartered in San Diego, California that is focused on developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology.

Got photos? Submit your photos here. ›

The takeaway

The mixed analyst views on Gossamer Bio highlight the challenges facing the company as it seeks to advance its pipeline of drug candidates through clinical trials and regulatory approvals. The 'Hold' rating could make it more difficult for the company to raise capital and fund its operations.